- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Is Botulinum toxin type A effective for treating and preventing cleft lip scarring? Study provides insights
China: Botulinum toxin type A (BTXA) can show better results in preventing and treating postoperative cleft lip and/or palate (CL/P) scar hypertrophy, according to new research in the Journal of Cosmetic Dermatology.
"We found no statistically significant difference between the findings after committing Chang's study or Navarro's study because of the injection time -- before/during surgery or adult CL/P scars," Junjie Chen, Department of Burn and Plastic Surgery, West China Hospital, Sichuan University, Chengdu, China, and colleagues wrote in their study.
Cleft lip and/or palate are congenital cleft facial deformities that are abnormal developments that result from the errors in the fusion process of the embryo's face. Surgery is an important treatment but postoperative scars will impact the patients' psychological health.
Against the above background, the team aimed to systematically evaluate the efficacy of BTXA in preventing and treating postoperative CL/P scars and improving scar quality.
For this purpose, the researchers performed a systematic review by searching the online databases for relevant trials. All relevant trials were performed before June 30, 2021. Data entry was done into Revman 5.3 software, and a random-effects model or fixed-effects model was used for conducting a meta-analysis.
The findings of the study were as follows:
- Four randomized controlled trials involving 161 cases were included.
- Through quantitative analysis, BTXA showed significant differences in preventing and treating postoperative CL/P scars in terms of scar width (MD: −0.20) and the Visual Analog Scale (VAS) (MD: 1.30), although no significant difference was noted on the Vancouver Scar Scale (VSS) (MD: −0.75) between the two groups.
"We found that BTXA injection can show better results in preventing and treating postoperative CL/P scar hypertrophy," wrote the authors.
"There was no statistically significant difference between the results after leaving out Chang's study or Navarro's study because of the time of injection—before/during surgery or adult CL/P scars."
Reference:
Ji Q, Tang J, Hu H, Chen J, Cen Y. Botulinum toxin type A for preventing and treating cleft lip scarring-A systematic review and meta-analysis. J Cosmet Dermatol. 2022 Jun;21(6):2331-2337. doi: 10.1111/jocd.14941. Epub 2022 Apr 11. PMID: 35347825.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751